Depósito Digital de Documentos de la UAB Encontrados 2 registros  La búsqueda tardó 0.01 segundos. 
1.
15 p, 418.2 KB Reducing residual thrombotic risk in patients with peripheral artery disease : impact of the COMPASS trial / Hernández, José Luis (Internal Medicine Department, Hospital Marqués de Valdecilla-IDIVAL, Universidad de Cantabria, Santander, Spain) ; Lozano, Francisco S (Department of Vascular Surgery, Hospital Clínico de Salamanca, Salamanca, Spain) ; Riambau, Vincent (Hospital Clínic i Provincial de Barcelona) ; Almendro-Delia, Manuel (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ; Cosín-Sales, Juan (Cardiology Department, Hospital Arnau de Vilanova. Facultad de Medicina, Universidad CEU-Cardenal Herrena, Valencia, Spain) ; Bellmunt-Montoya, Sergi (Hospital Universitari Vall d'Hebron) ; Garcia-Alegria, Javier (Department of Medicine, Hospital Costa del Sol, Marbella, Spain) ; Garcia-Moll, Xavier (Institut d'Investigació Biomèdica Sant Pau) ; Gomez-Doblas, Juan José (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Gonzalez-Juanatey, José R (Cardiology and Intensive Cardiac Care Department, University Hospital Santiago de Compostela, CIBERCV, Santiago de Compostela, Spain) ; Suarez Fernández, Carmen (Instituto de Investigación Hospital Universitario de la Princesa) ; Universitat Autònoma de Barcelona
Patients with peripheral artery disease (PAD) are at a high risk not only for the classical cardiovascular (CV) outcomes (major adverse cardiovascular events; MACE) but also for vascular limb events (major adverse limb events; MALE). [...]
2020 - 10.7573/dic.2020-5-5
Drugs in Context, Vol. 9 (july 2020)  
2.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.